NCT00550849View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Liver Disease
Interventions
DRUG

RTA 402

5 mg oral capsules

DRUG

RTA 402

25 mg oral capsules

DRUG

RTA 402

50 mg oral capsules

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00550849 - Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction | Biotech Hunter | Biotech Hunter